Satomi Shinonome
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Satomi Shinonome has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Azumi Ueyama
Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan
35 shared publications - Hidekazu Tanaka
Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan
35 shared publications - Hiroshi Yoshida
Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan
35 shared publications - Hiroto Miwa
Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan
35 shared publications - Hisashi Wada
Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Japan
35 shared publications - Mai Yoshikawa
Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan
35 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
The binding activity of S-531011 against various chemokine receptors, PD-1, PD-L1, CTLA4, or mouse CCR8
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
The binding activity of S-531011 against various chemokine receptors, PD-1, PD-L1, CTLA4, or mouse CCR8
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Binding profile of the newly created CCR8 antibody
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Binding profile of the newly created CCR8 antibody
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
In vivo anti-tumor activity of S-531011 in CT26.WT or EMT6 tumor-bearing mice model.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
In vivo anti-tumor activity of S-531011 in CT26.WT or EMT6 tumor-bearing mice model.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Generation of humanized CCR8 KI mice
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Generation of humanized CCR8 KI mice
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Concentration of S-531011 in serum and tumor after a single intravenous administration of S-531011 in CT26.WT tumor-bearing hCCR8 KI mice.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Concentration of S-531011 in serum and tumor after a single intravenous administration of S-531011 in CT26.WT tumor-bearing hCCR8 KI mice.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Data from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Although regulatory T cells (Treg) are inhibitory immune cells that are essential for maintaining immune homeostasis, Tregs that infiltrate tumor tissue promote tumor growth by suppressing antitumor immunity. Selective reduction of tumor-infiltrating Tregs is, therefore, expected to activate antitumor immunity without affecting immune homeostasis. We previously reported that selective Treg depletion targeted by a C-C motif chemokine receptor 8 (CCR8) resulted in induction of strong antitumor immunity without any obvious autoimmunity in mouse models. Thus, herein, we developed a novel humanized anti-CCR8 monoclonal antibody, S-531011, aimed as a cancer immunotherapy strategy for patients with cancer. S-531011 exclusively recognized human CCR8 among all chemokine receptors and showed potent antibody-dependent cell-mediated cytotoxicity activity toward CCR8+ cells and neutralization activity against CCR8-mediated signaling. We observed that S-531011 reduced tumor-infiltrating CCR8+ Tregs and induced potent antitumor activity in a tumor-bearing human-CCR8 knock-in mouse model. Moreover, combination therapy with S-531011 and anti-mouse programmed cell death 1 (PD-1) antibody strongly suppressed tumor growth compared with anti–PD-1 antibody alone with no observable adverse effects. S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These results suggest that S-531011 is a promising drug for inducing antitumor immunity without severe side effects in the clinical setting.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Although regulatory T cells (Treg) are inhibitory immune cells that are essential for maintaining immune homeostasis, Tregs that infiltrate tumor tissue promote tumor growth by suppressing antitumor immunity. Selective reduction of tumor-infiltrating Tregs is, therefore, expected to activate antitumor immunity without affecting immune homeostasis. We previously reported that selective Treg depletion targeted by a C-C motif chemokine receptor 8 (CCR8) resulted in induction of strong antitumor immunity without any obvious autoimmunity in mouse models. Thus, herein, we developed a novel humanized anti-CCR8 monoclonal antibody, S-531011, aimed as a cancer immunotherapy strategy for patients with cancer. S-531011 exclusively recognized human CCR8 among all chemokine receptors and showed potent antibody-dependent cell-mediated cytotoxicity activity toward CCR8+ cells and neutralization activity against CCR8-mediated signaling. We observed that S-531011 reduced tumor-infiltrating CCR8+ Tregs and induced potent antitumor activity in a tumor-bearing human-CCR8 knock-in mouse model. Moreover, combination therapy with S-531011 and anti-mouse programmed cell death 1 (PD-1) antibody strongly suppressed tumor growth compared with anti–PD-1 antibody alone with no observable adverse effects. S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These results suggest that S-531011 is a promising drug for inducing antitumor immunity without severe side effects in the clinical setting.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from S-531011, a novel anti-human CCR8 antibody, induces potent anti-tumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells
Concentration of S-531011 in serum and tumor after a single intravenous administration of S-531011 in CT26.WT tumor-bearing hCCR8 KI mice.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from S-531011, a novel anti-human CCR8 antibody, induces potent anti-tumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells
Concentration of S-531011 in serum and tumor after a single intravenous administration of S-531011 in CT26.WT tumor-bearing hCCR8 KI mice.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from S-531011, a novel anti-human CCR8 antibody, induces potent anti-tumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells
Generation of humanized CCR8 KI mice
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from S-531011, a novel anti-human CCR8 antibody, induces potent anti-tumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells
Generation of humanized CCR8 KI mice
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from S-531011, a novel anti-human CCR8 antibody, induces potent anti-tumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells
While regulatory T cells (Tregs) are inhibitory immune cells that are essential for maintaining immune homeostasis, Tregs that infiltrate tumor tissue promote tumor growth by suppressing anti-tumor immunity. Selective reduction of tumor-infiltrating Tregs is therefore expected to activate anti-tumor immunity without affecting immune homeostasis. We previously reported that selective Treg depletion targeted by a C-C motif chemokine receptor 8 (CCR8) resulted in induction of strong anti-tumor immunity without any obvious autoimmunity in mouse models. Thus, herein, we developed a novel humanized anti-CCR8 monoclonal antibody, S-531011, aimed as a cancer immunotherapy strategy for patients with cancer. S-531011 exclusively recognized human CCR8 among all chemokine receptors and showed potent antibody-dependent cell-mediated cytotoxicity activity toward CCR8+ cells and neutralization activity against CCR8-mediated signaling. We observed that S-531011 reduced tumor-infiltrating CCR8+ Tregs and induced potent anti-tumor activity in a tumor-bearing human-CCR8 knock-in mouse model. Moreover, combination therapy with S-531011 and anti-mouse programmed cell death 1 (PD-1) antibody strongly suppressed tumor growth compared to anti-PD-1 antibody alone with no observable adverse effects. S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These results suggest that S-531011 is a promising drug for inducing anti-tumor immunity without severe side effects in the clinical setting.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from S-531011, a novel anti-human CCR8 antibody, induces potent anti-tumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells
While regulatory T cells (Tregs) are inhibitory immune cells that are essential for maintaining immune homeostasis, Tregs that infiltrate tumor tissue promote tumor growth by suppressing anti-tumor immunity. Selective reduction of tumor-infiltrating Tregs is therefore expected to activate anti-tumor immunity without affecting immune homeostasis. We previously reported that selective Treg depletion targeted by a C-C motif chemokine receptor 8 (CCR8) resulted in induction of strong anti-tumor immunity without any obvious autoimmunity in mouse models. Thus, herein, we developed a novel humanized anti-CCR8 monoclonal antibody, S-531011, aimed as a cancer immunotherapy strategy for patients with cancer. S-531011 exclusively recognized human CCR8 among all chemokine receptors and showed potent antibody-dependent cell-mediated cytotoxicity activity toward CCR8+ cells and neutralization activity against CCR8-mediated signaling. We observed that S-531011 reduced tumor-infiltrating CCR8+ Tregs and induced potent anti-tumor activity in a tumor-bearing human-CCR8 knock-in mouse model. Moreover, combination therapy with S-531011 and anti-mouse programmed cell death 1 (PD-1) antibody strongly suppressed tumor growth compared to anti-PD-1 antibody alone with no observable adverse effects. S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These results suggest that S-531011 is a promising drug for inducing anti-tumor immunity without severe side effects in the clinical setting.